---
layout: post
title: "科伦药业：KL340399注射液瘤内注射治疗晚期实体瘤获批临床试验"
date: 2022-06-15 19:50:00 +0800
categories: zhengquanshibao
tags: 证券时报新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.002422" data-code="002422|0|2" data-code2="002422|0|6|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.002422&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 002422_0" data-code="K 002422|0|2" data-code2="K 002422|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>科伦药业(002422)6月15日晚间公告，公司控股子公司四川科伦博泰生物开发的新一代小分子STING激动剂(KL340399注射液)获得国家药监局签发新的临床试验通知书，同意按照提交的方案开展瘤内注射给药的临床试验。<br /></p><p class="em_media">（文章来源：证券时报）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202206152413974452>

[返回证券时报新闻](//finews.withounder.com/category/zhengquanshibao.html)｜[返回首页](//finews.withounder.com/)